These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 10748322)

  • 1. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia?
    Andreassen OA; Jørgensen HA
    Prog Neurobiol; 2000 Aug; 61(5):525-41. PubMed ID: 10748322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.
    Tsai G; Goff DC; Chang RW; Flood J; Baer L; Coyle JT
    Am J Psychiatry; 1998 Sep; 155(9):1207-13. PubMed ID: 9734544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid.
    Andreassen OA; Ferrante RJ; Beal MF; Jørgensen HA
    Neuroscience; 1998 Dec; 87(3):639-48. PubMed ID: 9758230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives.
    Kulkarni SK; Naidu PS
    Drugs Today (Barc); 2003 Jan; 39(1):19-49. PubMed ID: 12669107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Animal models of tardive dyskinesia--a review.
    Kulkarni SK; Naidu PS
    Indian J Physiol Pharmacol; 2001 Apr; 45(2):148-60. PubMed ID: 11480221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D(1A) receptor function in a rodent model of tardive dyskinesia.
    Van Kampen JM; Stoessl AJ
    Neuroscience; 2000; 101(3):629-35. PubMed ID: 11113312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroleptic-induced tardive dyskinesia.
    Jenner P; Marsden CD
    Acta Psychiatr Belg; 1987; 87(5):566-98. PubMed ID: 2897761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tardive dyskinesia: pathophysiology and animal models.
    Casey DE
    J Clin Psychiatry; 2000; 61 Suppl 4():5-9. PubMed ID: 10739324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia.
    Singh A; Naidu PS; Kulkarni SK
    Eur J Pharmacol; 2003 Sep; 477(2):87-94. PubMed ID: 14519411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tardive dyskinesia: review and update.
    Klawans HL; Goetz CG; Perlik S
    Am J Psychiatry; 1980 Aug; 137(8):900-8. PubMed ID: 6106395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral dyskinesias and morphological changes in rat striatum during long-term haloperidol administration.
    Andreassen OA; Meshul CK; Moore C; Jørgensen HA
    Psychopharmacology (Berl); 2001 Aug; 157(1):11-9. PubMed ID: 11512038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidative mechanisms and tardive dyskinesia.
    Lohr JB; Kuczenski R; Niculescu AB
    CNS Drugs; 2003; 17(1):47-62. PubMed ID: 12467492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies.
    Ouary S; Bizat N; Altairac S; Ménétrat H; Mittoux V; Condé F; Hantraye P; Brouillet E
    Neuroscience; 2000; 97(3):521-30. PubMed ID: 10828534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Occurrence of tardive dyskinesia during neuroleptic treatment].
    Fanget F; Henry E; Aimard G
    Presse Med; 1986 Dec; 15(43):2147-50. PubMed ID: 2884657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):451-61. PubMed ID: 17988775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clozapine in tardive dyskinesia: observations from human and animal model studies.
    Tamminga CA; Thaker GK; Moran M; Kakigi T; Gao XM
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():102-6. PubMed ID: 7961550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy.
    Bitton V; Melamed E
    J Clin Psychiatry; 1984 Jan; 45(1):28-30. PubMed ID: 6141157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pathophysiology of tardive dyskinesia.
    Klawans HL; Carvey P; Tanner CM; Goetz CG
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced number of striatal neurons expressing preprosomatostatin mRNA in rats with oral dyskinesias after long-term haloperidol administration.
    Andreassen OA; Finsen B; Ostergaard K; West MJ; Jørgensen HA
    Neurosci Lett; 2000 Jan; 279(1):21-4. PubMed ID: 10670778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.